Early reviews found patients in the monotherapy arms of both trials with PD-L1 low status had decreased survival compared to patients who received cisplatin- or carboplatin-based chemotherapy.
FDA - U.S. Food and Drug Administration
There are no news related to this product.
Registration is free.
myHealthbox can improve the online visibility of your products by as much as 20%.
Contact us to find out more.
myHealthbox™ is a leading provider of health information services to consumers and healthcare professionals.